331 East Evelyn Avenue
Founded in 1992, Conceptus (CPTS) is engaged in the design, development and marketing of innovative medical products for use in the field of women's health.
Conceptus is currently focused on marketing its Essure® permanent birth control system worldwide. With Essure, Conceptus believes it has the technology to transform the field of permanent birth control, and is in the process of marketing Essure globally.
In 2002, the U.S. Food and Drug Administration granted approval in November, 2002 to market Essure in the United States, a market where 700,000 tubal ligations and 400,000 vasectomies are performed annually.
The Essure procedure is a non-incisional alternative to tubal ligation, which is the leading form of birth control worldwide.
Tubal ligation involves abdominal incisions, general anesthesia, four to six days of recovery time and the risks associated with an incisional procedure.
The Essure procedure does not require incisions or general anesthesia. Essure can be performed in an outpatient setting, and women who have the procedure usually resume regular activities within 24-48 hours after the day of the procedure.
Essure is approved for sale in many countries, including the United States, Europe, Australia, Canada, Mexico, Central and South America, and New Zealand. Conceptus is working to make Essure available world-wide upon receipt of appropriate regulatory and/or governmental clearances.
Headquartered in the United States, Conceptus has twice been awarded "Fastest Growing Business in Silicon Valley (California).
Last Updated: 05-15-2007